UGC Approved Journal no 63975(19)

ISSN: 2349-5162 | ESTD Year : 2014
Call for Paper
Volume 11 | Issue 3 | March 2024

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 6 Issue 12
December-2019
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR1912110


Registration ID:
234392

Page Number

815-836

Share This Article


Jetir RMS

Title

“STRUCTURE BASED DRUG DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATIONOF (E)-4-($ CHLOROBENZYLIDENEAMINO)-6-PHENYL-3-THIOXO-3,4-DIHYDRO -1,2,4- TRIAZIN-5(2H)-ONE DERIVATIVES AS DYRK1A,CLK1A,GSK INHIBITORS”

Authors

Abstract

A sharp increase in the incident of Alzheimer’s disease (AD) especially in developed and developing countries is a matter of serious concern. It is predicted that 26 million people are affected by Alzheimer’s disease worldwide and it will be triple by the year 2050. There are two groups of drugs available on the market, which are classified according to their mechanism of action Inhibitors of acetyl cholinesterase and NMDA receptor inhibitors have beneficial effects on cognitive, functional, and behavioral symptoms of the disease, but their role in AD pathogenesis is unknown. Current treatments for AD provide only modest symptomatic relief. There is an urgent need for ‘disease modifying’ agents that slow the course of the disease and prevent or delay the disease in susceptible individuals.

Key Words

CLK (casein like kinase), Down syndrome, potential inhibitors, DYRK1A(Dual specificity tyrosine-phosphorylation-regulated kinase 1A)

Cite This Article

"“STRUCTURE BASED DRUG DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATIONOF (E)-4-($ CHLOROBENZYLIDENEAMINO)-6-PHENYL-3-THIOXO-3,4-DIHYDRO -1,2,4- TRIAZIN-5(2H)-ONE DERIVATIVES AS DYRK1A,CLK1A,GSK INHIBITORS”", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 12, page no.815-836, December-2019, Available :http://www.jetir.org/papers/JETIR1912110.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"“STRUCTURE BASED DRUG DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATIONOF (E)-4-($ CHLOROBENZYLIDENEAMINO)-6-PHENYL-3-THIOXO-3,4-DIHYDRO -1,2,4- TRIAZIN-5(2H)-ONE DERIVATIVES AS DYRK1A,CLK1A,GSK INHIBITORS”", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 12, page no. pp815-836, December-2019, Available at : http://www.jetir.org/papers/JETIR1912110.pdf

Publication Details

Published Paper ID: JETIR1912110
Registration ID: 234392
Published In: Volume 6 | Issue 12 | Year December-2019
DOI (Digital Object Identifier):
Page No: 815-836
Country: DATIA, Madhy pradesh, India .
Area: Pharmacy
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

0003114

Print This Page

Current Call For Paper

Jetir RMS